LBX Pharmacy Chain JSC
SSE:603883
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LBX Pharmacy Chain JSC
Net Issuance of Debt
LBX Pharmacy Chain JSC
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Net Issuance of Debt
-¥461.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
-20%
|
|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Net Issuance of Debt
-¥1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Net Issuance of Debt
¥155.3m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Net Issuance of Debt
¥170.3m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Net Issuance of Debt
-¥67.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
LBX Pharmacy Chain JSC
Glance View
LBX Pharmacy Chain JSC has emerged as a significant player in the pharmaceutical retail sector in China, riding the wave of increasing health consciousness and the aging population. Founded in a fast-paced, constantly evolving market, the company has strategically positioned itself to leverage this demographic shift. Its primary business model revolves around operating an extensive network of pharmacy outlets that serve both urban and rural customers. By offering a wide range of products, from prescription medications to health supplements and wellness goods, LBX ensures it caters to a diverse clientele, satisfying varying health care needs. The implementation of an omnichannel approach, integrating online and offline sales, has not only enhanced customer convenience but also expanded its reach, reinforcing its market position. Central to LBX’s profitability is its efficient supply chain management and strategic location of stores in high-traffic areas, which augments its accessibility and stock management capabilities. The company leverages partnerships with leading pharmaceutical manufacturers and distributors, securing competitive pricing and product availability. Additionally, its investment in technology bolsters its operational efficiency, enabling real-time inventory tracking and personalized customer service. This tech-driven approach enhances customer loyalty and provides insights into consumer behavior, guiding strategic decisions. Through a well-crafted blend of traditional retail expertise and innovative solutions, LBX Pharmacy Chain JSC continues to solidify its foothold in the market, driving revenue growth and expanding its reach across China.
See Also
What is LBX Pharmacy Chain JSC's Net Issuance of Debt?
Net Issuance of Debt
-461.5m
CNY
Based on the financial report for Mar 31, 2026, LBX Pharmacy Chain JSC's Net Issuance of Debt amounts to -461.5m CNY.
What is LBX Pharmacy Chain JSC's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
-20%
The average annual Net Issuance of Debt growth rates for LBX Pharmacy Chain JSC have been -63% over the past three years , -59% over the past five years , and -20% over the past ten years .